PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of new analyses from the pivotal Phase III CheckMate -9ER trial demonstrating ...

Three-year data – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib ...

People living with advanced renal cell carcinoma treated with the combination continued to report improvements in health-related quality of life 2 The safety profile at this longer follow-up in the ...

(RTTNews) - Exelixis, Inc. (EXEL) said data from a post-hoc exploratory analysis of the phase 3 CheckMate -9ER pivotal trial demonstrated efficacy benefits regardless of prior nephrectomy status with ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate ...

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status. Patients receiving ...

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to ...

“There is a continued need for new therapies that show benefit across subgroups of patients with advanced renal cell carcinoma,” said Robert Motzer, M.D., Kidney Cancer Section Head, Genitourinary ...

With a median follow-up of two years, Cabometyx in combination with Opdivo continues to demonstrate superior progression-free survival, overall survival and objective response rate compared to ...